Grifols S.A. (GRFS) vs Veradermics (MANE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Grifols S.A. is the larger company by market cap ($5.10 billion vs $4.64 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRFS | MANE |
|---|---|---|
| Share price | $7.50 | $110.95 |
| Market cap | $5.10B | $4.64B |
| 1-day change | -0.27% | +1.83% |
| YTD return | -19.79% | — |
| 1-year return | -21.79% | — |
| 5-year return | -47.26% | — |
| P/E ratio (TTM) | 9.74 | — |
| Forward P/E | 5.20 | — |
| EPS (TTM) | $0.77 | $-4.24 |
| Dividend yield | 1.40% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-70.00M |
| 52-week high | $9.90 | $131.24 |
| 52-week low | $6.96 | $32.00 |
| Distance from 52-week high | -24.24% | -15.46% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +44.93% | +47.36% |
| Average volume | 583.27K | 730.99K |
| Shares outstanding | 258.22M | 41.78M |
| Employees | 25,258 | 37 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Grifols S.A. offers a meaningfully higher dividend yield (1.40% vs 0.00%).
About Grifols S.A.
GRFS stock →Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.
Health Care · Biotechnology: Pharmaceutical Preparations · 25,258 employees
About Veradermics
MANE stock →Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
GRFS vs MANE FAQ
Which is bigger, Grifols S.A. or Veradermics?
Grifols S.A. (GRFS) is larger, with a market capitalization of $5.10B compared with $4.64B for Veradermics (MANE).
Which pays a higher dividend, Grifols S.A. or Veradermics?
Grifols S.A. pays a dividend yielding 1.40%, while Veradermics does not currently pay a regular dividend.
Are Grifols S.A. and Veradermics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.